Market Research Logo

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016’, provides in depth analysis on C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5)
  • The report reviews C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) Overview
Therapeutics Development
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Stage of Development
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Therapy Area
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Indication
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Products Glance
Late Stage Products
Early Stage Products
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Companies
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Universities/Institutes
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
American Gene Technologies International Inc.
ChemoCentryx, Inc.
Cytodyn Inc.
GlaxoSmithKline Plc
NeED Pharma s.r.l.
Pharis Biotec GmbH
Tobira Therapeutics, Inc.
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
(cenicriviroc mesylate + efavirenz + lamivudine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cenicriviroc mesylate + lamivudine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-1105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAL-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAL-MGMT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAL-X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCL-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-214096 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-4043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRO-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAP-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Dormant Projects
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Featured News & Press Releases
May 16, 2016: Clinical Abstract from CytoDyn’s PRO 140 Phase 2b HIV Monotherapy Trial Now Available on ASM Microbe 2016 Conference Website
May 13, 2016: Tobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients
May 03, 2016: CytoDyn’s Compassionate Use Protocol Receives FDA Clearance to Proceed
May 02, 2016: Tobira Announces Interim 12-week Results from the ORION Study
Apr 14, 2016: CytoDyn Files a Compassionate Use Protocol With FDA
Mar 09, 2016: Tobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials
Feb 09, 2016: Tobira Therapeutics Completes Patient Recruitment for ORION Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease
Jan 28, 2016: CytoDyn Reports Full Virologic Suppression in Eleven HIV Patients on PRO 140 Monotherapy for Up to 17 Months
Jan 22, 2016: CytoDyn Files Request for Breakthrough Therapy Designation With the FDA for Use of PRO 140 in HIV Therapy
Jan 20, 2016: CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
Jan 19, 2016: CytoDyn Announces HIV-Patients Approaching 17 Months of Complete Viral Suppression With PRO 140 Monotherapy
Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis
Dec 22, 2015: CytoDyn Files for Orphan Drug Designation for Use of PRO 140 in Graft Versus Host Disease
Dec 21, 2015: FDA Clears CytoDyn for Relaxed Entry Criteria for Its Ongoing Phase 3 Trial in HIV-Infected Patients
Dec 14, 2015: CytoDyn Receives FDA Clearance for Its First Non-HIV Indication for PRO 140
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by American Gene Technologies International Inc., H1 2016
Pipeline by ChemoCentryx, Inc., H1 2016
Pipeline by Cytodyn Inc., H1 2016
Pipeline by GlaxoSmithKline Plc, H1 2016
Pipeline by NeED Pharma s.r.l., H1 2016
Pipeline by Pharis Biotec GmbH, H1 2016
Pipeline by Tobira Therapeutics, Inc., H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report